Scoping Study Sample Clauses

Scoping Study. On April 16, 2008 the Company released a phosphate rock preliminary scoping study on its phosphate projects in Queensland conducted by British Sulphur, a division of CRU International. British Sulphur, the leading business consultancy in the fertilizer and inorganic chemical sector for over 50 years, have prepared initial project capital and operating costs assuming sale prices for phosphate of US$100 per tonne fob, US$200 per tonne fob, US$300 per tonne fob and US$400 per tonne fob. In March 2008, sales of Moroccan product at US$400 per tonne fob Morocco have been recorded. The report sets out the following gross earnings estimates (US$ millions) for the project: Current price case fob US$400/t rock Base case fob US$200/t rock High case fob US$300/t rock Worst case fob US$100/t rock Capital Cost(1) 826.6 826.6 826.6 826.6 Annual Revenue 2,000.0 1,000.0 1,500.0 500.0 Annual Costs 298.4 298.4 298.4 298.4 Annual Gross Earnings 1,701.7 701.7 1,201.7 201.7
Sample 1
AutoNDA by SimpleDocs
Scoping Study. Unless otherwise agreed, all work undertaken greater than an estimated value of £5,000 shall require a scoping study to be undertaken. This scoping study shall constitute an initial study, in collaboration with the client, and two “change iterations”. Subject to scope agreement, the price may vary. Work will not commence until formal agreement has been reached by scope sign off.
Sample 1
Scoping Study. Xxx Xxxx (60%)
Sample 1
Scoping Study. Xxx Xxxx (100%) Parts 1 and 2(1) Parts 1 and 2
Sample 1
Scoping Study. To establish the impact of Chalara on non- woodland trees in England.
Sample 1
Scoping Study. IFPRI Ondo State Sep 2015 1 Actual survey imple- mentation plan 1 ) Number of policy research and best practice papers gen- erated 4) Number of technical training courses offered to build technical skills and capacity for poli- cy analysis 5) Num- ber of individuals who have received USG supported short-term technical training in agricul- tural sector produc- tivity or food securi- ty policy analysis 2.8.1.2 Data Collection and training of government employees IFPRI Ondo State Nov-Dec 2015 1 Data collection and gov- ernment employees get training 2.8.1.3 Analysis XXXXX Xxxxxxxxxx and Abuja Jan-Apr 2016 1 Report of preliminary findings 2.8.1.4 Presentation IFPRI Abuja May-16 1 Literature review, draft paper, PowerPoint 2.8.1.5 Presentation IFPRI Washington Jun-16 1
Sample 1
Scoping Study. 2.8.1.2 Data Collection and training of government employees 2.8.1.3 Analysis 2.8.1.4 Presentation 2.8.1.5 Presentation
Sample 1
AutoNDA by SimpleDocs
Scoping Study. 2.8.2.4 Data Collection 2.8.2.5 Analysis 2.8.2.6 Presentation
Sample 1
Scoping Study. Subject to the Option being exercised in accordance with its terms, PGR shall prepare and complete the Scoping Study using the $500,000 of funding provided by the investment by the Investors and/or BGL/GMWU from the subscription for the 10% of the BGL equity, to compile , under BGL's supervision, all the past underground mining records and plans with respect to the Property as the first phase prior to a decision to commence a more detailed feasibility study to assess the longer term potential for a new underground mining development within the Property.
Sample 1

Related to Scoping Study

  • Feasibility Study 4.3.1 The Feasibility Study shall identify any potential adverse system impacts that would result from the interconnection of the Generating Facility.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Trials The Ship shall run the following test and trials:

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Project Initiation i - Upon final execution of the Agreement with the DISTRICT, the ARCHITECT shall: ♦ Review the Program Management Plan (PMP) with the DISTRICT and its representatives to familiarize them with the proposed tasks and schedule and develop necessary modifications. The PMP defines the Program Master Schedule and Budgets and each Project scope and budget.

Time is Money Join Law Insider Premium to draft better contracts faster.